<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632759</url>
  </required_header>
  <id_info>
    <org_study_id>IRB18-044</org_study_id>
    <nct_id>NCT03632759</nct_id>
  </id_info>
  <brief_title>Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D</brief_title>
  <official_title>Targeting Beta Cell Dysfunction in Longstanding T1D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carla Greenbaum, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benaroya Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can
      transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D)
      who secrete proinsulin and little/no C-peptide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>two independent open label, proof of concept studies</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of individuals with peak MMTT stimulated C-peptide &gt;0.017 pmol/mL.</measure>
    <time_frame>0-to-8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous (SC) liraglutide for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Golimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive subcutaneous (SC) golimumab for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Participants will receive subcutaneous (SC) liraglutide for 8 weeks</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>Participants will receive subcutaneous (SC) golimumab for 8 weeks</description>
    <arm_group_label>Golimumab</arm_group_label>
    <other_name>SIMPONI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 3 years from Type 1 diabetes diagnosis

          2. Males and females 18-50 years of age, inclusive

          3. Peak MMTT stimulated C-peptide &lt;0.017 pmol/mL

          4. Proinsulin levels ≥ 2 pM (either fasting or stimulated)

          5. Females of child-bearing potential must be willing to use effective birth control for
             12 weeks

          6. Willing and able to give informed consent for participation

          7. HbA1c ≤ 8.5%

        Exclusion Criteria:

          1. Concurrent use of non-insulin therapies aimed to control hyperglycemia or use within
             the past 30 days of screening MMTT (V-2).

          2. History of severe reaction or anaphylaxis to human, humanized or murine monoclonal
             antibodies.

          3. Diagnosis of liver disease or elevated hepatic enzymes, as defined by ALT or AST&gt; 1.5
             x the upper limit of age-determined normal (ULN) .

          4. Females who are pregnant or lactating.

          5. Receipt of an immune modulating biologic or investigational drug within 3 months or 5
             half-lives before enrollment.

          6. History of other clinically significant autoimmune disease needing chronic therapy
             with biologics or steroids with the exception of celiac and stable thyroid disease.

          7. Current use of any medication known to significantly influence glucose tolerance (e.g.
             oral steroids, atypical antipsychotics, diphenylhydantoin, niacin).

          8. Any medical or psychological condition that in the opinion of the principal
             investigator would interfere with the safe completion of the trial.

          9. For Study A (liraglutide)

               1. Any history of pancreatitis or elevated amylase or lipase.

               2. Any personal or family history of thyroid C-cell tumors, including medullary
                  thyroid carcinoma (MTC).

               3. Any personal or family history of multiple endocrine neoplasia syndrome type 2.

               4. Hypersensitivity to liraglutide.

               5. Previous treatment with liraglutide.

               6. Known history of clinically significant gastroparesis.

         10. For Study B (golimumab)

               1. Any history of recent (within 3 months) serious bacterial, viral, fungal, or
                  other opportunistic infections.

               2. Any history of demyelinating diseases (such as multiple sclerosis), heart
                  failure, or left ventricular dysfunction.

               3. Serologic evidence of current or past HIV, Hepatitis B, or Hepatitis C.

               4. Positive QuantiFERON or PPD TB test, history of tuberculosis, or active TB
                  infection.

               5. Active infection with EBV, defined by real-time PCR.

               6. Active infection with CMV, defined by real-time PCR.

               7. Any of the following hematologic abnormalities at screening:

                    -  White blood count &lt;3,000/μL or &gt;14,000/μL

                    -  Lymphocyte count &lt;500/μL

                    -  Platelet count &lt;140,000 /μL

                    -  Hemoglobin &lt;8.5 g/dL

                    -  Neutrophil count &lt;2,000 cells/μL

               8. Receipt of live vaccine (in the 6 weeks before treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Greenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benaroya Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marli McCulloch-Olson</last_name>
    <phone>1-800-888-4187</phone>
    <email>diabetes@benaroyaresearch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Benaroya Research Institute</investigator_affiliation>
    <investigator_full_name>Carla Greenbaum, MD</investigator_full_name>
    <investigator_title>Director, Diabetes Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

